A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

Show full item record



Permalink

http://hdl.handle.net/10138/159439

Citation

Seibold , P , Schmezer , P , Behrens , S , Michailidou , K , Bolla , M K , Wang , Q , Flesch-Janys , D , Nevanlinna , H , Fagerholm , R , Aittomaki , K , Blomqvist , C , Margolin , S , Mannermaa , A , Kataja , V , Kosma , V-M , Hartikainen , J M , Lambrechts , D , Wildiers , H , Kristensen , V , Alnaes , G G , Nord , S , Borresen-Dale , A-L , Hooning , M J , Hollestelle , A , Jager , A , Seynaeve , C , Li , J , Liu , J , Humphreys , K , Dunning , A M , Rhenius , V , Shah , M , Kabisch , M , Torres , D , Ulmer , H-U , Hamann , U , Schildkraut , J M , Purrington , K S , Couch , F J , Hall , P , Pharoah , P , Easton , D F , Schmidt , M K , Chang-Claude , J & Popanda , O 2015 , ' A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients ' , BMC Cancer , vol. 15 , 978 . https://doi.org/10.1186/s12885-015-1957-7

Title: A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
Author: Seibold, Petra; Schmezer, Peter; Behrens, Sabine; Michailidou, Kyriaki; Bolla, Manjeet K.; Wang, Qin; Flesch-Janys, Dieter; Nevanlinna, Heli; Fagerholm, Rainer; Aittomaki, Kristiina; Blomqvist, Carl; Margolin, Sara; Mannermaa, Arto; Kataja, Vesa; Kosma, Veli-Matti; Hartikainen, Jaana M.; Lambrechts, Diether; Wildiers, Hans; Kristensen, Vessela; Alnaes, Grethe Grenaker; Nord, Silje; Borresen-Dale, Anne-Lise; Hooning, Maartje J.; Hollestelle, Antoinette; Jager, Agnes; Seynaeve, Caroline; Li, Jingmei; Liu, Jianjun; Humphreys, Keith; Dunning, Alison M.; Rhenius, Valerie; Shah, Mitul; Kabisch, Maria; Torres, Diana; Ulmer, Hans-Ulrich; Hamann, Ute; Schildkraut, Joellen M.; Purrington, Kristen S.; Couch, Fergus J.; Hall, Per; Pharoah, Paul; Easton, Doug F.; Schmidt, Marjanka K.; Chang-Claude, Jenny; Popanda, Odilia
Contributor organization: Department of Obstetrics and Gynecology
Clinicum
Medicum
Kristiina Aittomäki / Principal Investigator
Department of Medical and Clinical Genetics
Department of Oncology
Date: 2015-12-16
Language: eng
Number of pages: 11
Belongs to series: BMC Cancer
ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1957-7
URI: http://hdl.handle.net/10138/159439
Abstract: Background: Personalized therapy considering clinical and genetic patient characteristics will further improve breast cancer survival. Two widely used treatments, chemotherapy and radiotherapy, can induce oxidative DNA damage and, if not repaired, cell death. Since base excision repair (BER) activity is specific for oxidative DNA damage, we hypothesized that germline genetic variation in this pathway will affect breast cancer-specific survival depending on treatment. Methods: We assessed in 1,408 postmenopausal breast cancer patients from the German MARIE study whether cancer specific survival after adjuvant chemotherapy, anthracycline chemotherapy, and radiotherapy is modulated by 127 Single Nucleotide Polymorphisms (SNPs) in 21 BER genes. For SNPs with interaction terms showing p <0.1 (likelihood ratio test) using multivariable Cox proportional hazard analyses, replication in 6,392 patients from nine studies of the Breast Cancer Association Consortium (BCAC) was performed. Results: rs878156 in PARP2 showed a differential effect by chemotherapy (p = 0.093) and was replicated in BCAC studies (p = 0.009; combined analysis p = 0.002). Compared to non-carriers, carriers of the variant G allele (minor allele frequency = 0.07) showed better survival after chemotherapy (combined allelic hazard ratio (HR) = 0.75, 95 % 0.53-1.07) and poorer survival when not treated with chemotherapy (HR = 1.42, 95 % 1.08-1.85). A similar effect modification by rs878156 was observed for anthracycline-based chemotherapy in both MARIE and BCAC, with improved survival in carriers (combined allelic HR = 0.73, 95 % CI 0.40-1.32). None of the SNPs showed significant differential effects by radiotherapy. Conclusions: Our data suggest for the first time that a SNP in PARP2, rs878156, may together with other genetic variants modulate cancer specific survival in breast cancer patients depending on chemotherapy. These germline SNPs could contribute towards the design of predictive tests for breast cancer patients.
Subject: Survival
Genetic variation
Chemotherapy
Radiotherapy
Anthracyclines
STRESS-RELATED GENES
POLY(ADP-RIBOSE) POLYMERASES
RISK
DOXORUBICIN
THERAPY
METAANALYSIS
EXPRESSION
RADIOTHERAPY
SURVIVAL
IMPACT
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
A_polymorphism_in_the_base_excision.pdf 1.023Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record